# X-Zell

Source: https://onco.cc/companies/x-zell/  
OnCo record `x-zell` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

X-Zell isolates rare abnormal cells from a blood sample and stains and images them so a pathologist can look for signs of cancer without a tissue biopsy.

## Summary

X-Zell, based in Bangkok with a German office, built an end-to-end platform for rare-cell detection: blood processing, isolation of circulating abnormal cells such as circulating endothelial cells, multiplex cytopathology staining and digital imaging, all developed in-house. Its early work centred on prostate cancer, where the aim was to reduce unnecessary biopsies after a raised PSA. The company remains active in the YC directory and describes a product ecosystem for research, companion diagnostics and relapse monitoring; it has not published pivotal clinical validation for a regulated test, so evidence should be treated as early.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: Bangkok
- Type: diagnostics
- Website: https://www.x-zell.com

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/x-zell
- Official website: https://www.x-zell.com

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Digital pathology & AI](https://onco.cc/technologies/digital-pathology-ai/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/x-zell.json